Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders for IRADIMED CORP held on June 15, 2023. The filing details the outcomes of six proposals submitted to security holders, including director elections, auditor ratification, executive compensation votes, and corporate governance amendments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance data.
Material Changes and Voting Results
The following material actions were approved or ratified by stockholders:
- Director Elections: Stockholders elected Roger Susi, Monty Allen, Anthony Vuoto, Hilda Scharen-Guivel, and James Hawkins to the Board of Directors. Hilda Scharen-Guivel received the highest support (10,900,200 votes for), while James Hawkins received the lowest (7,932,064 votes for).
- Auditor Ratification: RSM US LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 11,617,623 votes for.
- Executive Compensation: An advisory resolution on executive compensation was approved with 10,782,715 votes for. Stockholders also voted on the frequency of future advisory votes, with a majority (5,490,873 votes) selecting a 1-year frequency.
- Equity Incentive Plan: The Iradimed Corporation 2023 Equity Incentive Plan was approved with 8,665,347 votes for.
- Corporate Governance: An amendment to the Restated Certificate of Incorporation to limit the liability of certain officers was approved with 10,139,697 votes for.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of voting tallies and the formal approval of the listed proposals.
Investor Verification Checklist
- Verify the tenure and qualifications of the newly elected directors, particularly James Hawkins, who received the lowest vote count among nominees.
- Review the specific terms of the approved 2023 Equity Incentive Plan to understand potential dilution impacts.
- Confirm the details of the amendment limiting officer liability to assess changes in corporate governance protections.
- Check subsequent filings for the full financial results of the fiscal year ending December 31, 2023, as this 8-K does not contain financial statements.